
OR WAIT null SECS
Aleena Banerji, MD, discusses ALPHA-SOLAR interim data on navenibart dosed every 3 or 6 months for hereditary angioedema prevention at ACAAI 2026.
Navenibart, an investigational long-acting monoclonal antibody inhibitor of plasma kallikrein, reduced hereditary angioedema (HAE) attack rates by at least 90% with dosing every 3 or 6 months in interim results from the open-label ALPHA-SOLAR extension trial.1 Aleena Banerji, MD, professor of medicine at Harvard Medical School and clinical director of the Allergy and Clinical Immunology Unit at Massachusetts General Hospital, discussed the findings in an interview.
Banerji presented the interim data at the American College of Allergy, Asthma and Immunology (ACAAI) 2026 Annual Scientific Meeting, held November 12-16, 2026, in Phoenix, Arizona, amid a rapidly evolving HAE treatment landscape.2 ALPHA-SOLAR enrolled 29 adults who completed the earlier ALPHA-STAR trial and assigned them to navenibart 600 mg followed by 300 mg every 3 months (Arm A) or 600 mg every 6 months (Arm B).1 Banerji said a YTE modification to the Fc region extends the antibody's half-life well beyond the 3 to 4 weeks typical of IgG.
"I think there is a lot of benefit to having a drug that is dosed infrequently, right? We are talking about 2 to 4 injections in a year. And so I think the treatment burden is something that comes up a lot with our patients with hereditary angioedema," Banerji said.
Mean and median attack rates fell 92% and 97% in Arm A and 90% and 97% in Arm B from ALPHA-STAR baseline, and mean moderate or severe attack rates declined from 1.6 to 0.09 in Arm A and from 0.77 to 0.08 in Arm B.1 At 6 months, mean Angioedema Quality of Life Questionnaire (AE-QoL) total scores improved by 30.1 points in Arm A and 30.5 points in Arm B, exceeding the 6-point minimal clinically important difference.
Treatment-emergent adverse events (AEs) occurred in 69% of patients and were mostly mild, and Banerji said no drug-related serious AEs had been reported, with little difference between dosing arms to date. Navenibart is being evaluated in the phase 3 ALPHA-ORBIT (NCT06842823) and ORBIT-EXPANSE (NCT07204938) trials.1 These interim, open-label data have not been peer reviewed.
Banerji’s disclosures include Astria, Intellia, and Ionis.
References
Related Content: